POLB 001 data to be presented at ASH

Poolbeg Pharma PLC

06 November 2024

 

REACH

Poolbeg Pharma plc to present POLB 001 pre-clinical study data at the 66th American Society of Hematology (ASH) Annual Meeting

POLB 001 Reduces Cytokine Release Syndrome (CRS) in an in vivo animal model

Positive results reinforce POLB 001's potential in the prevention and treatment of cancer immunotherapy-induced CRS

ASH is the world's premier conference focussing on haematological malignancies

6 November 2024 - Poolbeg Pharma (AIM: POLB, 'Poolbeg' or the 'Company'), a clinical-stage biopharmaceutical company focussed on the development and commercialisation of innovative medicines targeting diseases with a high unmet medical need, today announces that it will present a poster detailing POLB 001's efficacy in reducing immunotherapy-induced CRS in an in vivo animal model, at the 66th American Society of Hematology ('ASH') Annual Meeting and Exposition, taking place 7-10 December 2024 in San Diego, California.

Poolbeg's poster presentation will provide insights into the results obtained from a POLB 001 in vivo study, a mouse model of immunotherapy-induced CRS. The positive results highlighted POLB 001's potential in the prevention and treatment of cancer immunotherapy-induced CRS. CRS can occur in >70%[1] of patients treated with T cell engaging bispecific antibodies, or CAR T cell therapies. CRS of any grade can lead to prolonged hospital stays and mortality risk. The administration of these cancer immunotherapies is therefore restricted only to specialist cancer centres, which has created a "bottleneck" in providing seamless, cost-efficient access to these treatments for the patients who need them.

Mark Sumeray MD, Consultant Clinical Advisor for Poolbeg, commented: "These data underscore the potential for POLB 001 to prevent or reduce the severity of CRS. If this effect is demonstrated in the clinic, this would enable broader, safer delivery of cancer immunotherapies, including in an out-patient setting. We look forward to sharing these important findings with the global hematology community at ASH."

Title: POLB 001, an Oral p38 MAPK Inhibitor, Reduces Cytokine Release Syndrome (CRS) in a Mouse Model of Immunotherapy-Induced CRS

Session Name: 703. Cellular Immunotherapies other than CAR-T Cells: Basic and Translational: Poster I

Session Date and Time: Saturday, 7 December 2024, 5:30 PM - 7:30 PM PST

Location: San Diego Convention Center, Halls G-H

Authors:  Liam Tremble, PhD, MSc, BSc, Paula Maguire, PhD, Jiwon Yang, PhD, James G Keck, Laura Maher, MSc, Mark Graham, Martin F Kaiser, MD, FRCP, FRCPath, Emma Searle, MD, PhD and Mark Sumeray, MD

Abstract Number: 2061

To schedule a meeting with the Company, please contact [e-mail].

Enquiries 

Poolbeg Pharma Plc  Jeremy Skillington, CEO  Ian O'Connell, CFO	[phone] [e-mail]
Cavendish Capital Markets Ltd (NOMAD & Joint Broker)  Geoff Nash, Camilla Hume, Trisyia Jamaludin (Corporate Finance) Nigel Birks (Life Science Specialist Sales) Harriet Ward (ECM)	[phone]
Shore Capital Stockbrokers Ltd (Joint Broker) David Coaten, Harry Davies-Ball (Corporate Advisory) Malachy McEntyre, Isobel Jones (Corporate Broking)	[phone]
J&E Davy (Joint Broker)  Anthony Farrell, Niall Gilchrist	[phone]
Optimum Strategic Communications  Nick Bastin, Vici Rabbetts, Elena Bates	[phone]  [e-mail]

About Poolbeg Pharma plc 

Poolbeg Pharma plc is a clinical-stage biopharmaceutical company focussed on acquiring, developing and commercialising innovative medicines that will help improve the lives of patients with rare and orphan diseases and where there is a high unmet medical need. Poolbeg comprises a strong and growing portfolio of development assets. For more information, please go to www.poolbegpharma.com or follow us on Twitter and LinkedIn @PoolbegPharma.

Forward-Looking Statements

This announcement may contain forward-looking statements and the words "expect", "anticipate", "intends", "plan", "estimate", "aim", "forecast", "project" and similar expressions (or their negative) identify certain of these forward-looking statements. The forward-looking statements in this announcement are based on numerous assumptions and Poolbeg's present and future business strategies and the environment in which Poolbeg expects to operate in the future. Forward-looking statements involve inherent known and unknown risks, uncertainties and contingencies because they relate to events and depend on circumstances that may or may not occur in the future and may cause the actual results, performance or achievements to be materially different from those expressed or implied by such forward-looking statements. These statements are not guarantees of future performance or the ability to identify and consummate investments. Many of these risks and uncertainties relate to factors that are beyond Poolbeg's ability to control or estimate precisely, such as future market conditions, currency fluctuations, the behaviour of other market participants, the outcome of clinical trials, the actions of regulators and other factors such as Poolbeg's ability to obtain financing, changes in the political, social and regulatory framework in which Poolbeg operates or in economic, technological or consumer trends or conditions. Past performance should not be taken as an indication or guarantee of future results, and no representation or warranty, express or implied, is made regarding future performance. No person is under any obligation to update or keep current the information contained in this announcement or to provide the recipient of it with access to any additional relevant information.

---

[1] Average rate from Summary of Product Characteristics (SmPCs) for Yescarta, Tecartus, Abecma, Kymriah, Carvykti, Breyanzi, Elrexfio, Columvi, Epkinly, Tecvayli and Talvey

 

END